Children born with inherited retinal dystrophies typically face a lifetime of diminishing vision and eventual blindness. But a new gene therapy - the first FDA-approved treatment for a genetic disorder - is revolutionizing our ability to preserve eyesight and improve quality of life in those affected. OHSU Casey Eye Institute was one of the first institutions in the U.S. to administer this sight-saving treatment, an accomplishment made possible because of its longstanding expertise in the field of ophthalmic genetics. Read more about advancing surgery in gene therapy.

OHSU Casey Eye Institute is a pioneer in the development of non-invasive imaging technology that offers unprecedented views of the inner eye and the ability to diagnose and manage eye disease in its earliest stages. Read more about OCT research at Casey.